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Abstract
Background: Non-medical prescription opioid (NMPO) use is a substantial public health problem in the United
States, with 1.5 million new initiates annually. Only 746,000 people received treatment for NMPO use in 2013,
demonstrating substantial disparities in access to treatment. This study aimed to assess correlates of accessing
substance use treatment among young adult NMPO users in Rhode Island, a state heavily impacted by NMPO use
and opioid overdose.
Methods: This analysis uses data from a study of 200 Rhode Island residents aged 18 to 29 who reported NMPO
use in the past 30 days. We compared individuals who had ever successfully enrolled in a substance use treatment
program without ever facing barriers, individuals who had ever attempted to enroll but were unable, and individuals
who never attempted to enroll. We used multinomial logistic regression to determine the independent correlates of
never attempting and unsuccessfully attempting to access substance use treatment.
Results: Among 200 participants, the mean age was 24.5, 65.5% were male, and 61.5% were white. Nearly half (45.5%)
had never attempted to enroll in substance use treatment, while 35.0% had successfully enrolled without ever facing
barriers and 19.5% were unsuccessful in at least one attempt to enroll. In multivariable models, non-white participants
were more likely to never have attempted to enroll compared to white participants. Previous incarceration,
experiencing drug-related discrimination by the medical community, and a monthly income of $501 - $1500
were associated with a decreased likelihood of never attempting to enroll. A history of overdose and a monthly
income of $501 - $1500 were associated with an increased likelihood of unsuccessfully accessing treatment.
The most commonly reported barriers to accessing treatment were waiting lists (n = 23), health insurance not
approving enrollment (n = 20), and inability to pay (n = 16).
Conclusions: This study demonstrates significant disparities in access to treatment among young adults who report
NMPO use. A history of overdose was shown to correlate with experiencing barriers to substance use treatment
utilization. Interventions are needed to reduce drug-related discrimination in clinical settings and to provide
mechanisms that link young adults (particularly with a history of overdose) to evidence-based treatment.
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Background
Non-medical prescription opioid (NMPO) use—defined
as intentional use of one’s own opioid prescription out-
side of prescribed parameters or use of an opioid with-
out a prescription [1, 2]—has become a major public
health problem in the United States [3]. There were 4.3
million active NMPO users in the United States in 2014
(representing 1.6% of the population), and 1.5 million
new initiates in 2013 [4, 5]. Opioid overdose has become
an epidemic in the United States, overtaking motor ve-
hicle crash mortality in 2009 [6]. There were 18,893 opi-
oid overdose deaths in 2014 compared to 16,235 in
2013, a year-over-year increase of 16% [7]. Yearly, opioid
overdose costs $20.4 billion due to lost productivity and
medical expenses [8]. Rhode Island has been heavily
impacted by NMPO use and opioid overdose. In 2015,
258 individuals died of an overdose, more than deaths
due to homicide, motor vehicle accidents, and suicide
combined [9, 10].
The prevalence of NMPO use is particularly high
among young adults; the percentage of users was highest
among 18- to 25-year-olds, reaching 2.8% in 2014 [4].
These rates of NMPO use trail only marijuana as the
most commonly reported drug of use among young
adults [4]. Among young adults, NMPO use has been
associated with transitioning to heroin use [11, 12]. Al-
though many individuals may initially receive opioids
through a prescription, adults ages 18 and above who
first obtain opioids illegally are more likely to transition
to heroin use [13–15].
A number of interventions, including state legislation
and clinical guidelines, have been shown to decrease
the public health burden associated with NMPO use
[16, 17]. For example, opioid use disorders can be treated
effectively with medication-assisted treatment (MAT) with
methadone, buprenorphine, or naltrexone [18, 19]. How-
ever, many of these strategies are grossly under-utilized
across the United States. Only 746,000 people in the
United States received treatment for NMPO use in 2013,
representing a sizable gap between utilization of care and
total reported use [5]. Nonetheless, this was more than
double the number of people who received care in 2002
[5]. Among youth with substance use disorders, only one in
ten individuals in the United States receives treatment [20].
The conceptual framework used to guide this paper is
adapted from the multilevel factors approach presented
by Kilbourne et al. [21]. This health services-oriented
approach to health disparities identifies three primary
determinants of health care access disparities—patient
factors, provider factors, and health care system factors,
as well as clinical encounters between patients and pro-
viders (see Fig. 1). Given that this conceptual framework
focuses on factors within the health care system, we have
adapted the model to additionally consider barriers from
outside of the system, such as interactions with govern-
ment services or police.
Patient-level factors and barriers
Research surrounding substance use treatment-seeking
behavior among adults is well established [22–24]. How-
ever, fewer studies have examined the treatment experi-
ences of young people who use prescription opioids
non-medically. Young adults ages 18 to 25 who report
NMPO use and perceive the need for treatment report
barriers to utilizing treatment, including an unwilling-
ness or lack of readiness to stop using, fear of negative
opinions when others find out about substance use (e.g.,
parents), a perceived ability to handle the problem on
Fig. 1 A multilevel approach to potential barriers to accessing substance use treatment among young NMPO users. NMPO: Non-medical prescription
opioid use. MAT: Medication-assisted treatment. Adapted from [21]
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their own, and a lack of knowledge regarding where to
obtain youth-friendly services [25]. Young NMPO users
have also shown lower rates of health education and
trust in health care providers compared to adult NMPO-
using populations [26, 27].
Provider-level factors and barriers
People who use opioids non-medically may not seek
substance use treatment due to important provider-level
factors such as perceived stigma, discrimination, and
other barriers experienced during clinical encounters
[28]. Adult NMPO users often have difficulty accessing
MAT in particular due to prescribing practices [29–31].
Prescribing buprenorphine requires physicians to obtain
a federal waiver, complete an eight-hour training, and meet
other criteria [30]. Prescribing buprenorphine is limited by
difficulties with reimbursement and professional training,
leading to a lack of prescribing physicians in many settings
throughout the United States [29, 31–33]. Provision of
methadone is similarly restricted by federal policies that
limit access for many patients [34]. For young adults,
treatment may not include MAT due to the fact that
many pediatricians do not have experience managing
patients on these medications or are not approved to
prescribe specific opioid agonist therapies (i.e., bupre-
norphine) [20, 33].
Health care system factors and barriers
Barriers to substance use treatment operating at the
health care system-level are present for all age groups.
Factors and barriers at the health care system-level in-
clude treatment program structure, waiting times, and
concerns regarding confidentiality [21, 35–38].
Individuals who are considering entering substance
use treatment may be hesitant due to doubt surrounding
their ability to meet a program’s criteria, including supervi-
sion, attendance, and abstinence [37]. Furthermore, waiting
lists represent a critical barrier to accessing treatment
[39, 40]. There is often a wide divergence between ex-
pected wait time among NMPO users and the actual
wait times that exist. A survey of 85 daily or almost
daily opioid users conducted in New Zealand showed
that participants eligible for opioid substitution therapy
estimated waiting times on average to be 6.5 days,
whereas the actual mean waiting time was 4.4 months
[38]. Total waiting times for substance use treatment in the
United States can also reach over two months [40]. In
young adult NMPO-using populations, waiting times, par-
ticularly for methadone clinics, remain understudied [29].
Young adults with substance use disorders face numerous
health care system barriers, including lack of insurance, in-
sufficiently integrated delivery systems, underfunding of
programs, and issues with patient confidentiality [36].
Furthermore, young adults may also fear that providers
will not or cannot keep their substance use confidential
from parents or other caregivers, reducing their likeli-
hood of seeking care [36].
Structural barriers
There are additional barriers to accessing substance use
treatment that exist outside of the health care system. In
some settings, NMPO users may choose not to seek
treatment due to a fear of disclosing illegal behavior to
the police, government, or other organizations [41]. In-
carceration, a structural factor, can act as a barrier by
interrupting treatment access among young adults who
use opioids non-medically [42]. However, incarceration
may also facilitate access to substance use treatment
through referrals and linkages to community-based pro-
viders [43]. Finally, previous studies have shown that
young adults who are homeless also have less success
accessing social services [44].
Objectives and hypothesis
This study aimed to assess patient-level, provider-level,
health care system, and structural factors associated with
substance use treatment access among young adults who
use prescription opioids non-medically. We also sought
to determine the risk factors associated with ever experi-
encing barriers while attempting to access substance use
treatment services. Our hypothesis was that patient-
specific, provider-centered, and health care system barriers
prevent young adults from successfully enrolling in care.
Methods
Study design and sample selection
This analysis uses data from the Rhode Island Young
Adult Prescription Drug Study (RAPiDS), a pilot study
of 200 Rhode Island residents aged 18 to 29 who re-
ported use of non-medical use of prescription opioids in
the past 30 days. Participants were recruited between
January 2015 and February 2016 through a combination
of targeted canvassing (TARC) and mixed internet-based
recruitment (MIBR). Specifically, recruitment for RAPiDS
was divided between two phases. In the first phase, eligible
participants were recruited via TARC. This recruitment
method relied primarily on bus advertisements and flyer-
ing in areas where drug-using young adults were known
to congregate. During this phase, individuals who com-
pleted the survey were also encouraged to refer friends
and acquaintances to the study. The second phase utilized
MIBR as a recruitment method, which included regular
posts on online classified sites (e.g., Craigslist), social
media (i.e., Facebook), and forums (e.g., Reddit).
In order to be eligible to participate in the study, individ-
uals needed to meet five criteria. These were: being aged
18 to 29 at the time of the interview, residing in Rhode
Island, not being currently involved in formal alcohol
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or substance use treatment, being able to complete an
interview in English, and providing informed consent.
Additionally, participants were required to confirm
non-medical use of prescription opioids in the past
30 days by indicating which opioids he or she recently
used non-medically, based on a modified version of the
Substance Abuse and Mental Health Service Administra-
tion’s “pill card A” [45]. No further eligibility restrictions
were specific to this analysis.
Eligible participants completed a computer-assisted
interview of approximately 45 min with a trained inter-
viewer. Sensitive portions of the survey were self-
administered using a computer. Individuals were offered
$25 for participating in the study. The Brown University
Institutional Review Board approved the study protocol.
Assessment of treatment utilization
The primary outcome for this analysis was self-reported
history of substance use treatment utilization. To define
this outcome, we divided the sample into three mutually
exclusive and collectively exhaustive groups. These
groups were conceptually defined as: (1) individuals who
had never attempted to enroll in substance use treat-
ment in their lifetime, (2) individuals who reported ever
enrolling in substance use treatment without ever being
unsuccessful in attempting to enroll, and (3) individuals
who were unsuccessful in at least one attempt to access
substance use treatment, regardless of whether or not
they had ever been in treatment. The operational defin-
ition of this outcome was a combination of two self-
reported binary variables. The first question asked if the
participant had ever been in any kind of alcohol or drug
treatment program (yes vs. no), which was defined as de-
tox, medication-assisted therapy, a group program (i.e.,
12-step AA or NA programs), outpatient day treatment,
or a residential drug treatment program. A follow-up
question asked all participants whether she/he had ever
tried to enroll in a substance use treatment program but
were unable to (yes vs. no).
Independent variables of interest
The RAPiDS survey instrument measured sociodemo-
graphic characteristics, patient-level factors, provider-level
factors, health care system factors, and structural factors.
The selection of variables to include in the analysis was
guided by our conceptual model and the a priori hypoth-
eses described above. Specifically, the analysis included
measures of sociodemographic factors such as age, sex,
ethnicity, race, sexual orientation, educational attainment,
employment, personal income, and geographic residence.
Age was defined as a continuous variable measured by
year, ranging from 18 to 29. Sex was defined as a binary
measure of sex at birth (male vs. female). Ethnicity was de-
fined as being of Hispanic or Latino descent (yes vs. no).
The race variable included the possible responses:
American Indian or Alaska Native, Asian, black (African,
Haitian, or of Cape Verdean descent), Native Hawaiian
or other Pacific Islander, white, mixed, bi-racial, or
multi-racial, and something else. For the purpose of
these analyses, the categories were collapsed into white
and non-white races. Sexual orientation was also col-
lapsed into two categories of straight vs. gay, lesbian,
bisexual, queer, or something else. Educational attainment
was measured by highest level of education received.
Employment was defined as being currently employed
full-time or part-time (yes vs. no). Personal income was
reported as monthly gross take home income, including
from public assistance or family support. Geographic
residence type used self-reported current ZIP code or
town of residence and was categorized as urban, subur-
ban, or rural according to standard US census defini-
tions and the Rhode Island land use survey [46].
We included any prior diagnoses of mental illness as
additional patient-level factors. Specifically, participants
were asked if she/he had ever been diagnosed with: at-
tention deficit hyperactivity disorder or attention deficit
disorder, obsessive-compulsive disorder, an eating dis-
order, a depressive disorder, bipolar disorder, an anxiety
disorder, psychosis, or another diagnosis. Additional
patient-level factors included in the analysis were ever
having overdosed by accident, ever having used heroin,
ever having used cocaine, and ever having used a needle
to chip, fix, muscle, or inject drugs.
The provider-level factors included in the analysis
were past history of being prescribed an opioid and ever
experiencing drug-related discrimination by the medical
community. Specifically, participants were asked to re-
port if she/he had felt discriminated against by the med-
ical community, such as a doctor, nurse, or clinic staff,
due to their drug use. This measure was adapted from
an item validated in a previous study examining stigma,
discrimination, and devaluation experienced by people
who use drugs [47].
We included self-reported current health insurance
status (yes vs. no) as a health care system-level factor.
Homelessness, a structural factor, was defined as ever
having been homeless. Other structural factors, such as
history of juvenile detention, arrest, and incarceration,
were assessed by asking individuals if she/he had ever
been detained in a juvenile detention center or training
school, ever been arrested, ever been detained or incar-
cerated in an adult jail, and ever been incarcerated in a
prison. Finally, participants were asked to report their
main barriers to accessing addiction treatment. The list
of possible response options was generated based on a
review of past literature that has examined barriers to
substance use treatment among young adults, and included
primarily health care system barriers, such as waiting lists,
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issues with health insurance, and programs that were
not youth-friendly or otherwise turned individuals down
[36, 40]. Participants could also state barriers that were
not listed.
Statistical analyses
First, we used descriptive statistics to summarize the
characteristics of the complete sample and each of the
three subsamples. Next, we conducted Pearson’s chi-
squared tests for categorical variables and ANOVA for
continuous variables in order to assess differences for
each variable across the three samples. We used Fisher’s
exact test when one or more of the cells included fewer
than 5 observations.
Third, we constructed a multivariable model using
multinomial logistic regression. In the model, individuals
who have never attempted to enroll (n = 91) and individ-
uals who were unsuccessful in at least one attempt to ac-
cess substance use treatment (n = 39) were compared
against individuals who have ever successfully enrolled
in substance use treatment without ever being unable to
enroll (n = 70). Variables that were found to be significant
at the p < 0.05 level in Table 2 were included in the original
model, as well as sex and recruitment source. To obtain a
more parsimonious model, we first calculated the variance
inflation factor for all sets of variables and removed those
that were found to be collinear. Next, a backwards elimin-
ation stepwise process was applied until at least one of the
effect estimates for each variable was significant at p < 0.05.
The final model was also adjusted for recruitment source
(TARC vs. MIBR), and all p-values are two-sided. Analyses
were conducted using Stata SE 13.1.
Results
Descriptive statistics
Among 200 participants, the mean age was 24.5 (SD =
3.24) and 65.5% (n = 131) of the sample was male. In the
sample, 14.0% (n = 28) of the participants were of His-
panic or Latino descent. The majority (n = 123, 61.5%)
was white and 38.5% (n = 77) were of another race.
Among the participants, 86.0% (n = 172) of the sample
reported sexual orientation as straight, and 13.5% were
lesbian, gay, bisexual, or queer (LGBQ) and other.
Among participants, 11.5% (n = 23) had less than a high
school education and 55.7% (n = 108) were unemployed.
The distribution of other patient, provider, health-
systems, and structural variables of interest are provided
in Table 1. Of note, the majority (n = 175, 87.5%) of the
sample had health insurance and had ever been home-
less (n = 109, 54.5%). Among participants, 29.5% (n = 59)
reported having experienced drug-related discrimination
by the medical community.
Approximately half (n = 91, 45.5%) of the sample had
never attempted to enroll in substance use treatment,
while 35.0% (n = 70) had ever successfully enrolled without
being unable to and 19.5% (n = 39) were unsuccessful in at
least one attempt to access treatment. Therefore, among
individuals who had ever attempted to access substance
use treatment (n = 109), 35.8% (n = 39) experienced bar-
riers preventing enrollment at least once. Of the 39 indi-
viduals who were unsuccessful in at least one attempt to
access treatment, 36 (92.3%) were successful in another at-
tempt to enroll. Among participants who reported ever
having successfully enrolled in substance use treatment,
the reported types of substance use treatment received
were an outpatient drug or alcohol treatment program
(n = 67, 63.2%), a self-help group (n = 61, 57.6%), detox
(n = 57, 53.8%), a residential drug treatment program
(n = 51, 48.1%), methadone or buprenorphine/naloxone
treatment (n = 48, 45.3%), a day treatment program or
partial hospitalization program (n = 25, 23.6%), and a
transitional halfway house (n = 1, 0.9%).
Among participants who were unsuccessful in enrolling
(n = 39), the most commonly reported barriers to acces-
sing substance use treatment were a waiting list (n = 23,
59.0%), health insurance not allowing enrollment (n = 20,
51.3%), an inability to pay (n = 16, 41.0%), being turned
down by a program (n = 12, 30.8%), not having health in-
surance (n = 8, 20.5%), no treatment programs being
nearby (n = 8, 20.5%), not knowing of any programs (n = 3,
7.7%), and programs not being youth-friendly (n = 3,
7.7%). Participants stated four barriers outside of the pro-
vided list; each had one response.
Correlates of accessing substance use treatment
Comparisons of the three treatment access groups are
shown in Table 2. We observed significant racial differ-
ences across the three groups. For example, only 27.1%
of those who had successfully enrolled in treatment
without ever facing barriers were non-white, compared
to 54.9% of those who had never attempted to access
treatment and 20.5% of those who had ever unsuccess-
fully attempted to enroll in treatment. Additionally, over
half (56.4%) of those who had ever been unsuccessful in
an attempt to enroll in treatment reported ever experien-
cing drug related discrimination by the medical commu-
nity, compared to only 37.1% of those who had successfully
enrolled in treatment.
The variance inflation factor between race and ever
using heroin was 1.32, demonstrating moderate collinear-
ity. Additionally, 61.8% of white participants ever used her-
oin, compared to only 10.4% of non-white participants.
The variance inflation factor between ever using heroin
and ever using a needle to inject drugs was 1.88, demon-
strating moderate collinearity. Ever using cocaine was also
moderately correlated with race and ever using heroin,
with variance inflation factors of 1.27 and 1.53, respectively.
Finally, the variance inflation factor between diagnoses of
Liebling et al. Substance Abuse Treatment, Prevention, and Policy  (2016) 11:38 Page 5 of 12
an anxiety disorder and a depressive disorder was 1.43,
demonstrating moderate collinearity. As such, heroin use,
cocaine use, lifetime injection drug use, and ever being di-
agnosed with a depressive disorder were excluded from the
final multivariable model. The variance inflation factor be-
tween past incarceration and detention in a juvenile deten-
tion center was 1.15, demonstrating low collinearity.
In the final model, factors independently associated
with never enrolling in substance use treatment compared
to participants who had successfully accessed treatment
without ever facing barriers are shown in Table 3. Com-
pared to white participants, non-white participants were
significantly more likely to have never attempted to enroll
in substance use treatment, with over three times the ad-
justed risk of never attempting to enroll compared to suc-
cessfully enrolling without ever facing barriers. Compared
Table 1 Characteristics of RAPiDS participants (n = 200)
Participants
200 (100%)
n (%)
Mean Age (Standard deviation) 24.5 (3.24)
Sex
Male 131 (65.5%)
Female 69 (34.5%)
Ethnicity
Hispanic or Latino descent 28 (14.0%)
Non-Hispanic 172 (86.0%)
Race
White 123 (61.5%)
Non-white 77 (38.5%)
Sexual orientation
Straight 172 (86.0%)
LGBQ and other 27 (13.5%)
Education
Less than high school 23 (11.5%)
High school/GED 76 (38.0%)
Beyond high school 101 (50.5%)
Employment status
Full or part-time 88 (44.0%)
Unemployed 108 (55.7%)
Monthly income
< $501 104 (52.0%)
$501 - $1500 58 (29.0%)
> $1500 35 (17.5%)
Geographic residence type
Rural 23 (11.5%)
Suburban 19 (9.5%)
Urban 151 (75.5%)
Ever overdosed by accident
Yes 53 (26.5%)
No 147 (73.5%)
Ever used heroin
Yes 85 (42.5%)
No 115 (57.5%)
Ever used cocaine
Yes 133 (66.5%)
No 67 (33.5%)
Ever used a needle to inject drugs
Yes 59 (29.5%)
No 140 (70.0%)
Ever diagnosed with…
ADHD/ADD 78 (39.0%)
Depression 95 (47.5%)
Table 1 Characteristics of RAPiDS participants (n = 200)
(Continued)
Anxiety 98 (49.0%)
Depression and anxiety 73 (37.0%)
Other (OCD, eating disorders, bipolar, etc.) 58 (29.0%)
Ever prescribed opioid
Yes 121 (61.1%)
No 77 (38.9%)
Drug-related discrimination by medical community
Yes 59 (29.5%)
No 141 (70.5%)
Insurance status
Yes 175 (87.5%)
No 25 (12.5%)
Ever detained in juvenile detention center
Yes 48 (24.0%)
No 152 (76.0%)
Ever arrested
Yes 141 (70.5%)
No 59 (29.5%)
Ever incarcerated in jail or prison
Yes 94 (47.0%)
No 106 (53.0%)
Ever homeless
Yes 109 (54.5%)
No 91 (45.5%)
Recruitment method
Field 79 (39.5%)
Internet 119 (59.5%)
Notes: Not all columns sum to 100% due to missing data and/or rounding
LGBQ Lesbian, gay, bisexual, or queer. GED General Education Development
ADHD/ADD Attention deficit hyperactivity disorder/attention deficit disorder
OCD Obsessive-compulsive disorder
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Table 2 Description of RAPiDS participants by history of utilization of substance use treatment (n = 200)
Attempted to enroll (n = 109)
Never attempted to enroll
91 (45.5%) n (%)
Successfully enrolled without
barriers 70 (35.0%) n (%)
Unsuccessfully attempted to
enroll 39 (19.5%) n (%)
χ2 (df) p - value
Mean Age (Standard deviation) 23.7 (3.23) 24.9 (3.30) 25.8 (2.60) 6.97 (2)a 0.001
Sex 5.44 (2) 0.066
Male 52 (57.1%) 52 (74.3%) 27 (69.2%)
Female 39 (42.9%) 18 (25.7%) 12 (30.8%)
Ethnicity (2)b 0.044
Hispanic or Latino descent 14 (15.4%) 13 (18.6%) 1 (2.6%)
Non-Hispanic 77 (84.6%) 57 (81.4%) 38 (97.4%)
Race 19.54 (2) <0.001
White 41 (45.1%) 51 (72.9%) 31 (79.5%)
Non-white 50 (54.9%) 19 (27.1%) 8 (20.5%)
Sexual orientation (2)b 0.431
Straight 75 (82.4%) 61 (87.1%) 36 (92.3%)
LGBQ and other 15 (16.5%) 9 (12.9%) 3 (7.7%)
Education 2.46 (4) 0.652
Less than high school 11 (12.1%) 6 (8.6%) 6 (15.4%)
High school/GED 32 (35.2%) 31 (44.3%) 13 (33.3%)
Beyond high school 48 (52.7%) 33 (47.1%) 20 (51.3%)
Employment Status 4.34 (2) 0.114
Full or part-time 46 (50.6%) 24 (34.3%) 18 (46.2%)
Unemployed 45 (49.5%) 46 (65.7%) 21 (53.9%)
Monthly income 15.84 (4) 0.003
< $501 39 (43.3%) 48 (70.6%) 17 (43.6%)
$501 - $1500 35 (38.5%) 9 (12.9%) 14 (35.9%)
> $1500 16 (17.6%) 11 (15.7%) 8 (20.5%)
Geographic residence type 5.62 (4) 0.229
Rural 9 (10.1%) 6 (9.2%) 8 (20.5%)
Suburban 6 (6.7%) 8 (12.3%) 5 (12.8%)
Urban 74 (83.1% 51 (78.5%) 26 (66.7%)
Ever overdosed by accident 24.99 (2) <0.001
Yes 10 (11.0%) 23 (32.9%) 20 (51.3%)
No 81 (89.0%) 47 (67.1%) 19 (48.7%)
Ever used heroin 58.87 (2) <0.001
Yes 13 (14.3%) 41 (58.6%) 31 (79.5%)
No 78 (85.7%) 29 (41.4%) 8 (20.5%)
Ever used cocaine (2)b <0.001
Yes 37 (40.7%) 61 (87.1%) 35 (89.7%)
No 54 (59.3%) 9 (12.9%) 4 (10.3%)
Ever used a needle to inject
drugs
(2)b <0.001
Yes 4 (4.4%) 28 (40.0%) 27 (69.2%)
No 86 (94.5%) 42 (60.0%) 12 (30.8%)
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to a monthly income of less than $501, a monthly income
of $501 - $1500 was associated with almost four times the
adjusted risk of never attempting to enroll in substance
use treatment compared to successfully enrolling in sub-
stance use treatment without ever facing barriers. This
was among the strongest associations found. Being of His-
panic or Latino descent, ever experiencing drug-related
discrimination by the medical community, and previous
incarceration were associated with a decreased risk of
never enrolling in substance use treatment compared to
successfully enrolling in substance use treatment without
ever facing barriers, adjusted for the other covariates.
Factors associated with ever being unable to enroll in
substance use treatment due to barriers compared to
successfully accessing treatment without ever facing bar-
riers are also presented in Table 3. Compared to partici-
pants who had successfully enrolled in substance use
treatment without ever facing barriers, a history of over-
dose and a monthly income of $501 - $1500 were associ-
ated with an increased adjusted risk of ever unsuccessfully
Table 2 Description of RAPiDS participants by history of utilization of substance use treatment (n = 200) (Continued)
Ever diagnosed
ADHD/ADD 27 (29.7%) 31 (44.3%) 20 (51.3%) 6.62 (2) 0.036
Depression 29 (31.9%) 43 (61.4%) 23 (59.0%) 16.42 (2) <0.001
Anxiety 37 (40.7%) 36 (51.4%) 25 (64.1%) 6.26 (2) 0.044
Other 22 (24.2%) 21 (30.0%) 15 (38.5%) 2.76 (2) 0.252
Ever prescribed opioid 0.24 (2) 0.886
Yes 53 (59.6%) 43 (61.4%) 25 (64.1%)
No 36 (40.5%) 27 (38.6%) 14 (35.9%)
Drug-related discrimination by
medical community
28.8 (2) <0.001
Yes 11 (12.1%) 26 (37.1%) 22 (56.4%)
No 80 (87.9%) 44 (62.9%) 17 (43.6%)
Insurance status (2)b 0.260
Yes 79 (86.8%) 59 (84.3%) 37 (94.9%)
No 12 (13.2%) 11 (15.7%) 2 (5.1%)
Ever detained in juvenile
detention center
11.29 (2) 0.004
Yes 13 (14.3%) 19 (27.1%) 16 (41.0%)
No 78 (85.7%) 51 (72.9%) 23 (59.0%)
Ever arrested 16.90 (2) <0.001
Yes 51 (56.0%) 57 (81.4%) 33 (84.6%)
No 40 (44.0%) 13 (18.6%) 6 (15.4%)
Ever incarcerated in jail or
prison
17.68 (2) <0.001
Yes 28 (30.8%) 42 (60.0%) 24 (61.5%)
No 63 (69.2%) 28 (40.0%) 15 (38.5%)
Ever homeless 12.03 (2) 0.002
Yes 40 (44.0%) 39 (55.7%) 30 (76.9%)
No 51 (56.0%) 31 (44.3%) 9 (23.1%)
Recruitment method 13.11 (2) 0.001
Field 24 (27.0%) 32 (45.7%) 23 (59.0%)
Internet 65 (73.0%) 38 (54.3%) 16 (41.0%)
Significance ascertained using a chi-square test unless otherwise noted
aSignificance tested using an ANOVA
bSignificance ascertained using a Fisher’s exact test
Notes: Not all columns sum to 100% due to missing data and/or rounding
LGBQ Lesbian, gay, bisexual, or queer
GED General Education Development
ADD/ADHD Attention deficit disorder/attention deficit hyperactivity disorder
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attempting to enroll in substance use treatment. Individ-
uals who reported having ever overdosed by accident had
over two and a half times the adjusted risk of having been
unsuccessful in an attempt to enroll in substance use
treatment compared to successfully enrolling in substance
use treatment.
Discussion
The results of this study demonstrate disparities in ac-
cess to and utilization of substance use treatment among
young adults who use prescription opioids non-medically.
Patient-level factors such as race and a history of acciden-
tal overdose were correlated with never attempting to en-
roll in substance use treatment and experiencing barriers
while attempting to access these services, respectively.
Although inference is limited by the small sample size,
these results nonetheless provide important insights into
patient-level barriers to addiction treatment among young
adults who report NMPO use, an understudied population
regarding access to care. Moreover, our results are consist-
ent with previous studies. A study of 1788 NMPO users
ages 12 to 17 found lower levels of perceived need for
substance use treatment among black individuals [48],
which could be an explanation for the lower levels of en-
rollment in substance use treatment among non-white
participants seen in this study. Alternatively, black individ-
uals may be less likely to ever enroll in treatment because
of mistrust of medical professionals due to a history of im-
plicit and explicit racial biases among providers in asses-
sing and undertreating pain and other conditions [49–52].
Previous analysis of provider-level barriers to accessing
treatment among street-involved youth and alcohol-
dependent men found perceptions of discrimination by
the medical community deter treatment seeking and
successful enrollment [44, 53]. Though the small sample
size limits inference, this conclusion is not supported by
the results of our multivariable analysis. However, ever
having experienced drug-related discrimination by the
medical community was among the strongest correlates
of successfully enrolling in substance use treatment
compared to never attempting to enroll, suggesting dis-
crimination experiences are, in part, due to an increased
level of interaction with the health care system. Although
the sample size was not large enough to test interactions
Table 3 Adjusted risk ratios of substance use treatment enrollment outcomes vs. successfully enrolling: RAPiDS (n = 200)
Never attempted to enroll (n = 91) Unsuccessfully attempted to enroll (n = 39)
Adjusted risk ratio 95% Confidence Interval (CI) p - value Adjusted risk ratio 95% Confidence Interval (CI) p - value
Ethnicity
Hispanic or Latino descent 0.30 (0.10, 0.95) 0.040 0.12 (0.01, 1.07) 0.058
Non-Hispanic 1.00 (Ref) 1.00 (Ref)
Race
White 1.00 (Ref) 1.00 (Ref)
Non-white 3.16 (1.28, 7.83) 0.013 1.39 (0.44, 4.43) 0.578
Monthly income
< $501 1.00 (Ref) 1.00 (Ref)
$501 - $1500 3.93 (1.53, 10.12) 0.005 5.36 (1.79, 16.03) 0.003
> $1500 2.16 (0.90, 5.80) 0.128 2.32 (0.74, 7.31) 0.151
Ever overdosed by accident
Yes 0.50 (0.19, 1.34) 0.169 2.71 (1.06, 6.91) 0.037
No 1.00 (Ref) 1.00 (Ref)
Drug-related discrimination by medical community
Yes 0.25 (0.10, 0.62) 0.003 1.33 (0.55, 3.27) 0.527
No 1.00 (Ref) 1.00 (Ref)
Ever incarcerated in jail or prison
Yes 0.31 (0.14, 0.66) 0.003 0.99 (0.40, 2.41) 0.977
No 1.00 (Ref) 1.00 (Ref)
Notes Model adjusted for recruitment source
The log likelihood of the model before stepwise removal is −151.39
The log likelihood of the model after stepwise removal is −157.95
The Nagelkerke R-squared of the model before stepwise removal is 0.478
The Nagelkerke R-squared of the model after stepwise removal is 0.432
The mean variance inflation factor for the model before stepwise removal is 1.33
The mean variance inflation factor for the model after stepwise removal is 1.15
The final model uses multinomial logistic regression and has 16 degrees of freedom
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between provider- and patient-level factors, it is possible
that non-white young adults are more likely to experience
drug-related discrimination by the medical community
than white young adults. Future research should focus on
assessing this disparity during attempts to access sub-
stance use treatment, and the ways in which discrimin-
ation may be experienced differentially by minority and
non-minority young adults. Additionally, medical training
should address the impact of drug-related discrimination
by the medical community and equip providers with the
skills and background necessary to deliver care in an ef-
fective, non-discriminatory manner.
Health care system-level factors were also present in
the analysis and were found to correlate with access to
substance use treatment. Supporting our finding, a pre-
vious analysis of barriers to utilizing drug and alcohol
treatment among street-involved youth found long wait-
ing lists to be the most common barrier [54]. Addition-
ally, 20 participants (10.0%) in our sample reported that
their health insurance did not allow enrollment; the ma-
jority (64.1%) of participants who were unsuccessful in
enrolling in substance use treatment cited at least one
health insurance-related barrier. Nonetheless, insurance
status was not found to have an effect on the likelihood
of attempting to enroll in substance use treatment in the
bivariate analyses. This may be due to high levels of insur-
ance in this sample of young adults (87.5%), which reflects
the fact that Rhode Island, as a Medicaid-expansion state,
has one of the highest insurance coverage rates in the na-
tion [55]. However, young adults with health insurance
may still face financial barriers to accessing substance use
treatment due to high deductibles and/or copayments, as
well as providers not accepting all types of insurance [36].
Thus, the high rates of health care system-level barriers
faced despite a high level of basic health insurance cover-
age in this sample point towards a need for additional fi-
nancial assistance programs for young adults who wish to
access substance use treatment.
In light of these findings, longitudinal studies are needed
to assess the association between changes in insurance
type and status over time and access to substance use
treatment services. For example, by comparing insurance
status and barriers to substance use treatment across time,
researchers can assess if individuals experience barriers
primarily before gaining insurance, or whether access to
care varies as a result of changing insurance provider. This
method would be particularly effective in determining the
impact of the Affordable Care Act on access to care and
treatment-seeking behavior.
With regard to structural factors, our analysis found
that past incarceration decreased the likelihood of never
enrolling in substance use treatment. This increase in
successful enrollments in care is likely due to mandatory
or facilitated interaction with the medical system among
individuals who were ever incarcerated or detained in a
juvenile detention center. Homelessness has previously
been found to be independently associated with an inability
to enroll in substance use treatment among street-involved
youth [43]; this conclusion is supported by the bivariate,
but not multivariable, analyses presented here. Home-
lessness may not be present in the multivariable models
due to the inclusion of other structural factors, such as
incarceration.
In order to increase access to substance use treatment
among young adults who report NMPO use, programs
should aim to engage the populations of young adults
who are not seeking treatment and those who have un-
successfully sought treatment. For example, a study of
hepatitis C virus treatment in the opioid agonist treat-
ment setting showed the impact of improved health care
system organization on access to care. The ETHOS
study, which utilized on-site care to improve the treat-
ment pathway and limit the use of unsuccessful referrals,
could be extended to treatment of young adults in order
to address a system of referrals that is unclear for med-
ical providers treating young adults attempting to begin
substance use treatment [36, 56]. Other public health
improvements that may result in increased access to
substance use treatment include removing age restrictions
and/or improving age transitions across a continuum of
services, youth-specific housing with integrated addiction
treatment services, and peer-led services [44, 57].
Limitations
This study has a number of limitations that should be
noted. First, the study relied on self-reported data, which
may be subject to under-reporting or socially desirable
reporting biases. To minimize the potential for these biases,
sensitive portions of the survey were self-administered
using a computer. Second, this study relied on cross-
sectional data. This analysis uses lifetime experiences in-
stead of exposures with shorter recall periods (e.g., within
the past month) where applicable in an effort to maintain
consistency with the recall period for the outcome of inter-
est. Nonetheless, given the cross-sectional nature of our
data, precise temporality cannot be ascertained. Therefore,
the results of this analysis are purely correlative. We were
not able to differentiate between treatment specifically re-
lated to opioid use disorder compared to treatment for
other drugs, or between an opioid overdose or overdose
due to other drug use. Additionally, we did not measure
why individuals never attempted to access treatment.
We did not have sufficient sample size to compare (in
a multivariable model) individuals who experienced bar-
riers with those who had never experienced barriers.
Additionally, the sample size resulted in some small cell
sizes, which increased the type II error rate and could
have resulted in an inability to detect meaningful
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differences between groups. Moreover, our use of a step-
wise model-building process and multiple tests increased
the likelihood of type I error; as such, marginally signifi-
cant associations should be interpreted with caution.
The eligibility criteria used did not include a formal diag-
nosis of an opioid use disorder, meaning that some partici-
pants may not be eligible for certain types of treatment
(e.g., opioid agonist therapy). Finally, although diverse
methods were used to recruit participants residing
throughout the state of Rhode Island, this population was
not randomly sampled and does not include partici-
pants who are currently involved in formal alcohol or
substance use treatment, meaning the sample likely
underrepresents individuals who have been successful
in accessing substance use treatment. These factors
may limit the generalizability of the study outside of
young adults who use prescription opioids non-
medically and are not currently enrolled in substance
use treatment.
Conclusions
This exploratory study demonstrates significant dispar-
ities in access to substance use treatment among young
adults who report NMPO use in Rhode Island. Patient-
level factors, such as being non-white and past overdose
were shown to correlate with never attempting to enroll
in substance use treatment and experiencing barriers to
substance use treatment utilization, respectively. Public
health interventions, including, for example, improved
medical training in the management and treatment of
substance use disorders among young people and the
integration of substance use treatment services within
youth-specific shelters and housing programs, are needed
to reduce drug-related discrimination in clinical settings
and to provide mechanisms that link young adults with
treatment.
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